Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A (CIP2A): an oncoprotein with many hands

Pradip De _, Jennifer Carlson, Brian Leyland-Jones and Nandini Dey

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2014; 5:4581-4602. https://doi.org/10.18632/oncotarget.2127

Metrics: PDF 3221 views  |   HTML 4108 views  |   ?  


Pradip De1,2, Jennifer Carlson1, Brian Leyland-Jones1,2 and Nandini Dey1,2

1 Department of Molecular & Experimental Medicine, Avera Research Institute, Sioux Falls, SD

2 Department of Internal Medicine, SSOM, University of South Dakota, Sioux Falls, SD


Nandini Dey, email:

Keywords: CIP2A, PP2A, c-MYC, Cancers, Prognosis, Biomarkers

Received: April 16, 2014 Accepted: June 20, 2014 Published: June 22, 2014


Oncoprotein CIP2A a Cancerous Inhibitor of PP2A forms an “oncogenic nexus” by virtue of its control on PP2A and MYC stabilization in cancer cells. The expression and prognostic function of CIP2A in different solid tumors including colorectal carcinoma, head & neck cancers, gastric cancers, lung carcinoma, cholangiocarcinoma, esophageal cancers, pancreatic carcinoma, brain cancers, breast carcinoma, bladder cancers, ovarian carcinoma, renal cell carcinomas, tongue cancers, cervical carcinoma, prostate cancers, and oral carcinoma as well as a number of hematological malignancies are just beginning to emerge. Herein, we reviewed the recent progress in our understanding of (1) how an “oncogenic nexus” of CIP2A participates in the tumorigenic transformation of cells and (2) how we can prospect/view the clinical relevance of CIP2A in the context of cancer therapy. The review will try to understand the role of CIP2A (a) as a biomarker in cancers and evaluate the prognostic value of CIP2A in different cancers (b) as a therapeutic target in cancers and (c) in drug response and developing chemo-resistance in cancers.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 2127